Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00428090
First received: January 25, 2007
Last updated: February 13, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2008
  Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: October 13, 2010